Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

SELL
$0.39 - $0.71 $8,419 - $15,328
-21,589 Reduced 3.59%
579,400 $241,000
Q4 2022

Feb 13, 2023

SELL
$0.33 - $10.44 $53,917 - $1.71 Million
-163,386 Reduced 21.38%
600,989 $242,000
Q3 2022

Nov 14, 2022

BUY
$0.92 - $11.16 $385,917 - $4.68 Million
419,475 Added 121.62%
764,375 $650,000
Q2 2022

Aug 12, 2022

SELL
$1.02 - $1.83 $1.37 Million - $2.45 Million
-1,339,206 Reduced 79.52%
344,900 $400,000
Q1 2022

May 13, 2022

BUY
$1.06 - $2.1 $1.17 Million - $2.32 Million
1,103,806 Added 190.21%
1,684,106 $2.38 Million
Q4 2021

Feb 11, 2022

SELL
$2.05 - $3.2 $210,944 - $329,280
-102,900 Reduced 15.06%
580,300 $1.19 Million
Q3 2021

Nov 12, 2021

BUY
$2.54 - $4.07 $503,174 - $806,267
198,100 Added 40.84%
683,200 $2.1 Million
Q2 2021

Aug 13, 2021

SELL
$2.57 - $4.85 $1.45 Million - $2.75 Million
-566,019 Reduced 53.85%
485,100 $1.97 Million
Q1 2021

May 13, 2021

BUY
$1.9 - $2.82 $1.97 Million - $2.93 Million
1,038,619 Added 8308.95%
1,051,119 $2.6 Million
Q4 2020

Feb 10, 2021

BUY
$1.15 - $2.4 $14,374 - $30,000
12,500 New
12,500 $27,000
Q1 2020

May 14, 2020

SELL
$1.26 - $3.38 $118,944 - $319,072
-94,400 Closed
0 $0
Q4 2019

Feb 13, 2020

BUY
$0.86 - $1.44 $81,184 - $135,936
94,400 New
94,400 $126,000
Q3 2019

Nov 13, 2019

SELL
$1.21 - $1.59 $1.18 Million - $1.56 Million
-979,200 Closed
0 $0
Q2 2019

Aug 12, 2019

SELL
$1.25 - $3.14 $137,500 - $345,400
-110,000 Reduced 10.1%
979,200 $1.48 Million
Q1 2019

May 14, 2019

BUY
$2.79 - $4.09 $947,205 - $1.39 Million
339,500 Added 45.28%
1,089,200 $3.22 Million
Q4 2018

Feb 13, 2019

BUY
$3.23 - $7.01 $2.42 Million - $5.26 Million
749,700 New
749,700 $2.52 Million

Others Institutions Holding VSTM

About Verastem, Inc.


  • Ticker VSTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 210,000,000
  • Market Cap $1.09B
  • Description
  • Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...
More about VSTM
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.